Editorial
|
|
|
|
|
Weighing the risks of drugs during pregnancy
|
|
|
|
New Products
|
|
|
|
|
No justification for using this anticoagulant after an acute coronary syndrome
|
|
|
|
|
|
|
|
|
|
More data needed on this dangerous antitubercular drug
|
|
|
|
|
|
|
|
|
|
Wait for conclusive results on complications of diabetes
|
|
|
|
|
|
|
|
|
|
Hypertensive crises during surgery: no advance
|
|
|
|
|
|
|
|
|
|
|
|
An alternative to abiraterone after docetaxel failure
|
|
|
|
Adverse Effects
|
|
|
|
|
4 epidemiological studies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
To be discontinued gradually
|
|
|
|
|
|
|
|
|
|
Several dozen reports worldwide
|
|
|
|
|
|
|
|
|
|
Monitoring blood cell counts is essential
|
|
|
|
|
|
|
|
|
|
Advanced age and renal failure are risk factors
|
|
|
|
|
|
|
|
|
|
Prevention includes double-checking
|
|
|
|
Reviews
|
|
|
|
|
Choice of treatment
|
|
|
|
|
|
|
|
|
|
|
|
Multidrug-resistant tuberculosis: treatment is empirical, for want of robust trials
|
|
|
|
|
|
|
|
|
|
As effective as 14 days of therapy
|
|
|
|
|
|
Outlook
|
|
|
|
|
Independence of WHO INN programme must be safeguarded
|
|
|
|
|
|
|
|
|
|
Regulators are complacent
|
|
|
|
|
|